Key Points Clearmind Medicine’s Chief of Global Impact, Mary-Elizabeth Gifford, testified at the FDA’s September 14 hearing on the potential future therapeutic use of psychedelic…
September 17, 2026
September 17, 2026
Aethlon Medical Merges With North Immunology to Advance NOR-101 for Atopic Dermatitis
Key Points Aethlon Medical will merge with privately held North Immunology in an all-stock transaction. The combined company will operate as North Immunology, Inc. and is expected…
September 17, 2026
Aquestive Resubmits Anaphylm New Drug Application Following New FDA-Requested Studies
Key Points Aquestive Therapeutics has resubmitted its New Drug Application for Anaphylm™, a needle-free epinephrine treatment candidate for severe allergic reactions, including anaphylaxis. The resubmission…
Key Points Alzamend Neuro has regained compliance with Nasdaq’s continued-listing requirements. The company reported stockholders’ equity of approximately $5.8 million as of July 31, 2026,…
Key Points Pulse Biosciences completed enrollment of 100 patients in its PRECISE-BTN clinical study. The study is evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for…
September 15, 2026
Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates
Key Points Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series. The allowance…
September 14, 2026
FDA Approves Telix’s Pixclara for Glioma Brain Cancer Imaging
Key Points The FDA approved Telix Pharmaceuticals’ Pixclara® for PET imaging in patients with glioma, a form of brain cancer. Pixclara is the first FDA-approved…
Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…
September 11, 2026
Cardiol Therapeutics Files US$150 Million Shelf Prospectus Ahead of CardiolRx Milestones
Key Points Cardiol Therapeutics filed a preliminary US$150 million base shelf prospectus in Canada and a related Form F-10 registration statement with the U.S. Securities…
September 11, 2026
NRx’s HOPE Therapeutics Prepares First Robotic TMS Deployment in Florida
Key Points NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics. HOPE…
September 10, 2026
Rhythm Highlights Setmelanotide Benefits in Pediatric Hypothalamic Obesity Studies
Key Points Rhythm Pharmaceuticals presented real-world and Phase 3 data on setmelanotide in children with acquired hypothalamic obesity at ESPE 2026. A French early-access analysis…
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…